Skip to main content
. 2018 Mar 23;31(1):35–42.

Figure 3.

Figure 3

Percentage of different subgroups of patients (n = 10) who have achieved SVR12 with sofosbuvir/ledipasvir + rivabirin (SOF/LDV + RBV).